Galaxy Diagnostics

Galaxy Diagnostics We offer advanced diagnostic test solutions that go beyond the limits of detection for low- abundance pathogens.

We test for a range of flea and tick-borne pathogens, specializing in Bartonella, Borrelia, and Babesia. Galaxy Diagnostics is building awareness about Bartonella as a potential cause of disease in animals and humans. The purpose of this page is to share the latest Bartonella research and other developments related to this important area of emerging infectious disease. The CDC reports that over 60% of emerging infectious diseases are zoonotic (from animals). Vectors (insects and arthropods) play an important role in transmission of zoonotic diseases. The One World, One Health Initiative was launched recently to focus attention on the intersections between human health, animal health, and the health of the environment. It is critical that medical practitioners and public health workers become aware of the risk factors and clinical symptoms associated with all zoonotic infections, including the ones linked to chronic disorders.

03/27/2026

We need to start examining the infectious causes behind neurological and cognitive changes.

For Galaxy Diagnostics CEO Nicole, this understanding came through personal experience.

About a decade ago, her husband’s personality began to change. Therapy didn’t help, and lab after lab came back normal.

Finally, doctors diagnosed him with early-onset Alzheimer’s.

It wasn’t until nearly two years later, when specialty testing revealed he was actually positive for multiple tick-borne infections, including Lyme, Bartonella, and Babesia.

By the time the diagnosis came, his neurological decline was severe. Nicole’s husband passed away in 2022.

Experiences like this are why Galaxy exists.

Our mission is to help equip providers with better tools to detect complex tick-borne infections, so patients and families have a better chance of finding answers sooner.

Babesiosis may be far more common than the initial numbers suggest.Survey data from indicates cases could be undercount...
03/26/2026

Babesiosis may be far more common than the initial numbers suggest.

Survey data from indicates cases could be undercounted by as much as 25× – with an estimated 46,000 U.S. cases annually, compared to 1,834 reported by the CDC.
Improving both clinical awareness and improving diagnostic sensitivity is essential to understanding the true scope of disease burden – particularly for stealth pathogens like Babesia.

We’re committed to helping move that progress forward.

Lyme disease doesn’t always occur in isolation.Ticks frequently carry more than one pathogen. In fact, in one study, nea...
03/24/2026

Lyme disease doesn’t always occur in isolation.

Ticks frequently carry more than one pathogen. In fact, in one study, nearly 45% of infected Ixodes ticks harbored multiple organisms.

And yet, testing practices don’t always reflect that reality.

When co-infections aren’t considered, they’re less likely to be identified. And when they’re missed, patients are left dealing with prolonged symptoms while providers must navigate with incomplete data.

Co-infections require clinical awareness, and advanced diagnostic strategies designed to detect them.

Swipe to explore what that means – and why it matters.

03/23/2026

Not all tick and vector-borne disease testing uses the same approach. Here are 3 reasons infections are so often missed – and how we’re changing the standard.

1️⃣ Timing of testing: Tick-borne infections don’t stay at consistent levels in the bloodstream. Early in infection, antibodies may not yet be detectable. Later, microbes may circulate at very low or intermittent levels, which can result in a negative test even when infection is present.

2️⃣ Using antibody-based testing alone: Most tests measure the body’s immune response rather than the pathogen itself. Antibody production can vary, especially after prior treatment. As a result, antibody-only testing doesn’t always reflect active infection.
3️⃣ Assay sensitivity and methodology: Differences in sample preparation, target selection, and quality controls influence whether small amounts of microbial DNA are identified. When sensitivity is limited, these low-level infections can go undetected.

At Galaxy Diagnostics, we approach tick-borne testing differently.

Instead of relying solely on immune response, we focus on direct molecular detection – identifying microbial DNA using advanced PCR-based methodologies designed for high sensitivity.

Because when providers have better tools, patients get better answers.

03/20/2026

The blood–brain barrier is protective – but it’s not impenetrable.

In our recent educational webinar, Jennifer C. Miller, PhD, of Galaxy Diagnostics, explained how Bartonella may breach this barrier through multiple mechanisms.

And once inside the central nervous system, the effects can be wide-reaching.

This might include symptoms from neuropathic pain and cognitive dysfunction to mood changes, encephalopathy, and, in rare cases, more severe complications.

As Dr. Miller emphasized, improving diagnostic accuracy starts with understanding what these organisms are biologically capable of.

Link in bio to watch the full webinar to explore the science behind Bartonella and the evolving approach to advanced tick-borne detection.

Lyme and tick-borne disease awareness is growing – and we’re absolutely thrilled to see it happening. It validates what ...
03/20/2026

Lyme and tick-borne disease awareness is growing – and we’re absolutely thrilled to see it happening.

It validates what both clinicians and patients have been seeing for years.

But awareness is only the first step.

What really makes change is action – stronger science, better diagnostics, and scalable innovation.

We’re proud to be part of that next phase, including bringing Dr. Brandon Jutras’s innovative peptidoglycan antigen detection technology into our diagnostic pipeline through our partnership with .tech

Momentum is building. Now let’s translate it into impact 💚

We’re excited to share an update from the LymeX Diagnostics Prize Challenge!Galaxy Diagnostics has joined forces with Dr...
03/19/2026

We’re excited to share an update from the LymeX Diagnostics Prize Challenge!

Galaxy Diagnostics has joined forces with Dr. Brandon Jutras and his team to help advance Lyme disease diagnostics.

The translation from the research lab to the clinic is being led by Jennifer Miller, PhD, our Vice President of Clinical and Scientific Operations. With over 20 years of experience in vector-borne pathogens, she oversees clinical assay development and validation at Galaxy – and has previously collaborated with Dr. Jutras.

By combining Galaxy’s expertise in vector-borne disease testing with Dr. Jutras’ groundbreaking research on Borrelia peptidoglycan, we’re working to accelerate new approaches for detecting Lyme infection.

As our CEO Nicole Bell shared: “Over more than 25 years of bringing new technologies to market, I’ve learned one lesson repeatedly: silos kill innovation.”

We know that progress in complex diseases like Lyme doesn’t happen in isolation. It happens through collaboration.

We’re proud to be part of the LymeX initiative and to help move the field of Lyme diagnostics forward.

Tick-borne infections aren’t difficult to diagnose because clinicians aren’t looking hard enough.They’re difficult to di...
03/18/2026

Tick-borne infections aren’t difficult to diagnose because clinicians aren’t looking hard enough.

They’re difficult to diagnose because the biology is complex.

Many tick-borne pathogens are built for survival.They migrate into tissues, fluctuate in the bloodstream, interfere with immune signaling. Some may be detectable one day and nearly invisible the next.

So a test that captures a single moment in time may not always capture the full picture.

In a recent webinar, Jennifer C. Miller, PhD, of Galaxy Diagnostics, explained how understanding pathogen behavior inside the human body is foundational to improving diagnostic accuracy.

Link in bio to watch the full webinar to explore the science behind tick-borne testing – and how advanced diagnostics are evolving to meet the challenge.

Lyme and tick-borne disease testing isn’t simple – and current standards may be missing a lot of cases.A 20-year meta-an...
03/17/2026

Lyme and tick-borne disease testing isn’t simple – and current standards may be missing a lot of cases.

A 20-year meta-analysis found average Lyme test sensitivity between 54–60%. That means a meaningful percentage of infections may go undetected.

When these diagnostic tools are so limited, the consequences extend beyond just statistics. Patients are left without answers, and providers are forced to navigate complex cases without the data they need.

The biology of these stealth pathogens is complex. Our diagnostic strategies need to reflect that complexity.

If we want clearer answers, we have to be willing to examine where the gaps exist – and why.

Swipe to explore what makes tick-borne diagnostics so challenging, and where progress is happening.

03/12/2026

Changing the standard of care means thinking bigger than growing one specialty lab.

Galaxy Diagnostics is focused on making advanced testing accessible, scalable, and integrated into everyday clinical practice. That means bringing innovation into the mainstream, improving access, and working toward coverage so more patients can benefit.

Our vision is simple: better diagnostics, available to everyone who needs them.
Learn more about our work at https://www.galaxydx.com/

Feedback from providers like Dr. Casey Kelley of reinforces why high-quality diagnostics matter in Lyme and vector-born...
03/11/2026

Feedback from providers like Dr. Casey Kelley of reinforces why high-quality diagnostics matter in Lyme and vector-borne disease care.

We’re deeply grateful for the clinicians who put their trust in our work. Your commitment to patients and willingness to dig deeper inspires everything we do.

Thank you for joining in our mission to change the standard of care in vector-borne disease.

When symptoms don’t leave, diagnostic answers are more important than ever.This case follows a 39-year-old patient with ...
03/09/2026

When symptoms don’t leave, diagnostic answers are more important than ever.

This case follows a 39-year-old patient with complex neurological and systemic symptoms that continued despite prior Lyme treatment and conflicting test interpretations. With high exposure risk in an endemic region, the next step was clear: look deeper.

Galaxy Diagnostics’ multiplex dPCR identified Bartonella, helping support a more targeted treatment plan.

While treatment is still early, cases like this remind us how much the right answers can change the direction of care.

Address

6 Davis Drive
Durham, NC
27709

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+19193139672

Website

Alerts

Be the first to know and let us send you an email when Galaxy Diagnostics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Galaxy Diagnostics:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category